Li Junfang, Wang Xiaodong, Zhang Honghua, Hu Xiaoling, Peng Xue, Jiang Weifan, Zhuo Linsheng, Peng Yan, Zeng Guo, Wang Zhen
School of Pharmacy, Lanzhou University, Lanzhou, Gansu, China.
School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Med Res Rev. 2025 Jan;45(1):164-213. doi: 10.1002/med.22079. Epub 2024 Aug 22.
Fenamates as classical nonsteroidal anti-inflammatory agents are widely used for relieving pain. Preclinical studies and epidemiological data highlight their chemo-preventive and chemotherapeutic potential for cancer. However, comprehensive reviews of fenamates in cancer are limited. To accelerate the repurposing of fenamates, this review summarizes the results of fenamates alone or in combination with existing chemotherapeutic agents. This paper also explores targets of fenamates in cancer therapy, including COX, AKR family, AR, gap junction, FTO, TEAD, DHODH, TAS2R14, ion channels, and DNA. Besides, this paper discusses other mechanisms, such as regulating Wnt/β-catenin, TGF-β, p38 MAPK, and NF-κB pathway, and the regulation of the expressions of Sp, EGR-1, NAG-1, ATF-3, ErbB2, AR, as well as the modulation of the tumor immune microenvironment. Furthermore, this paper outlined the structural modifications of fenamates, highlighting their potential as promising leads for anticancer drugs.
非甾体抗炎药作为经典的非甾体抗炎药,被广泛用于缓解疼痛。临床前研究和流行病学数据凸显了它们在癌症化学预防和化疗方面的潜力。然而,关于非甾体抗炎药在癌症方面的全面综述较为有限。为加速非甾体抗炎药的重新利用,本综述总结了非甾体抗炎药单独使用或与现有化疗药物联合使用的结果。本文还探讨了非甾体抗炎药在癌症治疗中的靶点,包括COX、AKR家族、AR、间隙连接、FTO、TEAD、DHODH、TAS2R14、离子通道和DNA。此外,本文讨论了其他机制,如调节Wnt/β-连环蛋白、TGF-β、p38 MAPK和NF-κB通路,以及调节Sp、EGR-1、NAG-1、ATF-3、ErbB2、AR的表达,以及对肿瘤免疫微环境的调节。此外,本文概述了非甾体抗炎药的结构修饰,突出了它们作为抗癌药物潜在先导化合物的潜力。